PHE Director of Screening Professor Anne Mackie explains that it is important that healthcare policy makers do not risk undermining or overlapping with NHS population screening.
Non-invasive prenatal testing (now more commonly called cfDNA, or cell-free DNA testing) is an exciting development and the UK NSC is now consulting on introducing it to the existing fetal anomaly screening programme (FASP). As new technology can only be introduced …
The UK’s processes and standards for reviewing screening policy and making screening recommendations are recognised and respected as world leading.
“The only reason for time is so that everything doesn't happen at once” (Albert Einstein) The NHS Screening Programmes have their own way of making sure everything “doesn’t happen at once”. We have the antenatal and newborn screening timeline which (below …
One of the biggest challenges we face is raising awareness of the importance of screening among those people most at risk of the condition we are testing for.
Each year, around 3,500 babies – or 1 in 200 of all those born in England – have some kind of heart defect.
I'm sure we'd all say that it's important to listen but sometimes we only do it with half an ear - or perhaps not at all.
In today’s blog post we’d like to tell you about the great progress we’ve made with the Newborn Blood Spot Failsafe Solution (NBSFS).
I’m sure you’re all very aware of the big changes we’ve made recently to the NHS Fetal Anomaly Screening Programme (FASP). From April 2015, eligible pregnant women in England started to be offered first trimester combined screening for Trisomy 18 (Edwards’ …
Population screening programmes provide compelling evidence that early intervention reduces the burden of disease and improves health.
In our blog last week, we introduced the key performance indicators for screening and how they can help drive local improvements in screening services. In this follow-up blog, we’re going to look at the last KPI data we published.